SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-23-031458
Filing Date
2023-09-06
Accepted
2023-09-05 19:56:16
Documents
13
Period of Report
2023-09-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cpix-20230905.htm   iXBRL 8-K 30545
2 EX-10.1 cumberlandpharm-arloanagre.htm EX-10.1 277235
  Complete submission text file 0001628280-23-031458.txt   483117

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cpix-20230905.xsd EX-101.SCH 2013
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cpix-20230905_lab.xml EX-101.LAB 24139
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cpix-20230905_pre.xml EX-101.PRE 12611
7 EXTRACTED XBRL INSTANCE DOCUMENT cpix-20230905_htm.xml XML 2828
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33637 | Film No.: 231237507
SIC: 2834 Pharmaceutical Preparations